Stats

The Darden market-control instability and the censored live record do not show a positive edge. The data shows that DARDEN has a 76.280% event mean, with a confidence interval of -1.49818% to 2.52709% and 4 out of 6 wins with a Wilson score of 0.29999 to 0.90323. The source of this data is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=DRI,SPY&feed=sip&adjustment=all. An ordinary least squares analysis of DRI's return on gross compared to the same window for SPY shows a train alpha of 0.251474%, beta of 0.190686, and correlation of 0.202725, but the test alpha is -0.278871%, beta is -1.678656, and correlation is -0.902852. The test mean excess return is 1.38334%, but this does not establish a stable alpha due to sign reversal, small sample size, and post-selection bias. The benchmark holds from T5 to T1 close, while DRI exits intraday, resulting in different exposure durations. A review of the query trades fund catalyst ledger shows three closed trades with 0 wins, a mean loss of 16.380601%, and a realized loss of 31.937258 USD. Two operator liquidations censored the intended horizons. The largest loss was 45.860062%, which was due to a listed stop loss of 6.440348. There is no observed average winner, and actual entry quotes history is absent, so execution's spread and slippage cannot be separated from gaps and monitor latency. The operational Kelly criterion is 0. The validity of the positive expected return is not identified by three heterogeneous losses or six selected paper returns. The soundness of the results is limited by sampling and censoring, and the fact that 0 out of 3 trials were successful does not provide confidence in the strategy. Additionally, the first run losses do not disprove the new strategy, and genuinely new prospective data would change confidence. It is also important not to pool operator liquidations with planned stop or target outcomes as if they were identical trials.

A simulation, called a Monte Carlo, was run with specific assumptions to analyze Darden's stock. The simulation used 50,000 possible paths, starting at $49.14, and was based on historical data from the past, not predictions of future trades. The data was taken from a source that provides stock prices at 15-minute intervals. The simulation showed that if Darden's stock had a 1% chance of losing 20% of its value per event, the potential loss would be 26.59% and the maximum potential loss would be 22.16%. However, these assumptions were not based on actual risks associated with Darden's stock. The simulation also showed that if Darden's stock experienced a shock, the potential loss would be higher. The results of the simulation were recorded and analyzed. The analysis showed that the potential payoff was approximately equal to the risk. However, the simulation had limitations, such as not being able to account for extreme events that were not observed in the historical data. Based on the analysis, it was concluded that no allocation should be made to Darden's stock, as the potential risks outweighed the potential benefits. A news scan found the headline, but this is a detailed explanation of a data analysis. The analysis used a method called the Kelly criterion to determine the optimal amount of capital to allocate to Darden's stock, but the results showed that the optimal allocation was zero. The analysis also showed that the potential shortfall, or loss, was $349.01 per month, but this was not included in the model.

A news scan found the text describing the Darden indicator's performance. Premises use only pre-entry indicators, with green exit stress payoffs from the DARDEN06 audit 1832, sourced from https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=DRI&timeframe=15Min&feed=sip&adjustment=all with SIP daily. The results show positive 20-day momentum training with a mean of -0.56733%, and testing with a mean of +1.53465%. The trend SMA 50 was positive, with training and testing means of -0.18623% and +1.43563%, respectively. Combined trend and momentum training had a mean of -0.56733%, and testing had a mean of +1.43563%, with a confidence interval of [-0.35844, 3.07784]%. The SPY was above the 200 SMA, with training and testing means of -0.68158% and +1.80542%, respectively. In contrast, when the SPY was below the 200 SMA, the training mean was +1.57002%, and the testing mean was -4.45028%. The favorable test confidence interval was above 0 in selected 4/5 groups, but this does not establish a stable filter due to training direction reversals and unadjusted multiple comparisons. The ATR/cut training median was 1.702676%, with high volatility training and testing means of +0.80897% and +0.98705%, respectively. The current close on September 9 was 209.42, below the 20 SMA of 219.0445 and the 50 SMA of 209.453, with a 20-day momentum of -4.33074%. This is not an entry window, as of September 17. The conclusion is that no adopted indicator combination was found, and there was no holdout refit. The validity is affected by instability and small N block calibration, and the soundness is affected by selected events, interdependence, and current versus future fundamental regimes. A counter case true conditioned edge may exist, but it requires prespecified prospective events, not reweighting these 18.

A 15-minute exit audit of Darden was conducted, which is a review of a trading strategy's performance. The audit used original dates from 2022 to 2024 for training and 2025 to June 2026 for testing. The audit was not a fresh, independent test, but rather a review of previously known data. The audit verified 18 earnings dates and 6 advance notices. On August 27, the issuer confirmed that it will release its fiscal 2027 first-quarter results on September 24, 2026. The trading strategy involved buying at 9:30 and forcing a sale at 15:45. The strategy had a 20% stop loss and a 1.5% target, with a sell signal at a 1% gain. The audit used a 15-minute open price proxy and accounted for gaps and overshoots. It also included 10 basis point fees and a 10 basis point liquidity cost. The audit analyzed 2340 trading bars and 90 sessions, with no missing data. The results showed a 6.65% return on investment for the training period and a 6.35% return for the testing period. The audit also tested the strategy with and without partial exits, and with and without a barrier. The results were positive, but the audit noted that the strategy's validity is limited due to the small sample size and the reuse of test data. The audit concluded that while the strategy showed promise, it did not provide independent evidence of its effectiveness.

A new conference call time for Innate Pharma, ticker IPHA, has been confirmed for September 17 at 08:00 EDT or 14:00 CEST, as stated on their website. This replaces an earlier uncertain reference to 09:00 ET. The first financial release time is still unresolved and there is no statement about receiving 75 million from Sobi. The current webpage is valid, but it differs from a prior journal entry that contained an error description. Meanwhile, FedEx, ticker FDX, has changed its fiscal year end from May 31 to December 31, effective June 1, which includes a 7-month transition period and a freight spinoff. This change makes the assumed September 17 historical calendar lead unsafe and no verified replacement earnings date has been obtained. As a result, the IPHA monitor will be updated, but the conditional financing forecast will be retained, and the FDX date-based entry will be rejected. This update is about a conference scheduling change and does not affect cash or stock payoff. The soundness of this decision is based on issuer assertions and bounded indexes, and it is possible that future news may affect this decision. However, even if there is strong trial funding or FedEx restructuring, calendar precision does not estimate a positive expected return. This is for research purposes only and there is zero allocation.

A news scan found the headline about a deep-dive decision on IPHA. The question is whether Sobi will remove financing pressure before the September 17 results or just move it into the trial. The current funding baseline is 49.14 fund cash and 850.99 equity, with no holdings or queued orders. The goal is to achieve repeatable pre-event gains. A binding constraint is an independent executable edge, and there is fundamental uncertainty about closing cash and retained trial costs. The analysis is based on the following premises: 1. The 1990 recovery analysis shows that August 14 conditional combined runway Q1 2028 supersedes August 10 upfront-only Q3 2027. The equity is completed, but the Sobi 75m receipt is still unverified, and the March financial assets are not current cash. 2. Innate conducts a trial, but the historical 326 participant design and late 2020s timeline until 2038 do not prove budget coverage or future gap. Future milestones and royalties are the strongest counterargument to the financing bear case. 3. A frozen 1997 calendar test shows train N12-29.10%, holdout N6-10.46%, and stress-13.11%, with no positive costed Kelly and no independent post-Sobi sample. 4. The technical 2025 median USD 56.6k and 25 share affordability do not fix the edge or liquidity. 5. The simulation 2026 historical tail is not risk-bound, and the statistical 2024 regression is not causal alpha. The conclusion is that the fundamental WATCH improves, but trading is rejected, with a proposed size of 0. The validity is necessary, but the edge gate fails. The soundness is bounded by a single issuer small N, incomplete first news archive, daily fill/+1R limitations, and missing current cash, full contract, and current deck. Additional primary searches repeat finance facts, and it is better to stop rather than invent receipt, trial cost, or approval odds. There is no proposal to exit, adjust, or fund. The sources of information include SEC archives and press releases from Sobi and Innate Pharma. The next follow-up is scheduled for 17:40:06 UTC, and the research took approximately 14 minutes to complete.

The fund started with $49.14 in cash and $850.99 in equity, with no open positions. The goal is to make repeatable gains before a documented event, with the condition that the net payoff must be positive. The first gate passed for the September 17 financials, but the first release minute is still unclear due to overlapping news from the September 14 conference and other clinical news. The fundamental evidence improved, with a conditional combined runway until Q1 2028, although payment receipt and trial-cost sharing are still unverified. However, the price context is weak, with the close being $1.95 below the 20/50 SMA, a 20-day loss of 9.30%, and a median turnover of 56.6k. The frozen calendar test from 1997 failed, and all 18 historical entries failed the adopted 1m turnover screen. The Quarter Kelly formula resulted in a value of 0, which is binding before the fund cap of $49.14, position cap of 212.7475, or equity risk cap of 8.5099. In conclusion, there is no proposal. Positive fundamental news alone is not enough to make all necessary conditions true, and the strongest counterexample is the new financing regime, which has no independently measured payoff cohort yet. The sources used include the Innate Pharma financial calendar, SEC filings, and stock bars data.

A news scan found the following information about Sobi's financing changes. There are three premises: 1. The August 10 agreement exchanges conditional cash for commercial rights and a later development option, with Innate conducting TELLOMAK3. 2. The August 14 and 19 equity adds 27.6 million euros expected net and 17.65 million shares, funding ADC priority. 3. Existing Phase 2 evidence and historical randomized design are not current Phase 3 results. A positive chain of events includes: first, closing funds trial start or filing and improves funding flexibility; second, potential accelerated approval permits Sobi commercialization while Innate keeps milestone and royalty rights; third, paid uptake, ongoing PFS confirmation, cost sharing, and net dilution determine per-share cash. An adverse chain of events includes: first, closing or trial delay consumes cash; second, milestone deferral or expenses can revive financing need; third, additional dilution or program prioritization can reduce existing holder upside. Sobi gets staged exposure and a future option, Innate gets time and resources, and trial vendors may get spend. A strong counterargument is that early royalties and milestones could bridge future costs, therefore the funding gap is not asserted as certain. The full cost schedule, option conditions, and current budget remain missing. Historical 2025 deck 326 planned participants and late 2020 timeline illustrate a distinction only, not a new dated catalyst. Clinical sources are issuer-biased, joint releases count once. There is no peer or fund proposal without a price edge. Sources include press releases from Sobi and Innate Pharma, and a deck from a KOL event.

A clinical financing headline does not estimate stock-return tails. A test using 50,000 draws from 248 overlapping 5-session blocks of IPHA stock prices over the last 252 sessions found that the potential loss could be -15.06024%, the median change could be -0.56818%, and the potential gain could be +17.73050%. The frequency of a loss was 54.094%. If the full $49.14 million exposure were invested, the potential loss could be $7.40060, but this is not the worst-case scenario and no allocation was approved. This test assumes the future will be like the recent past, which may not account for unexpected events. An alternative test used a fixed exchange rate of 0.8, 0.9, and 1.0 euros per US dollar and estimated that the company could have 27.6 million euros in new equity, plus 75 million US dollars, which equals 87.6 to 102.6 million euros. This could fund the company for 14.6 to 51.3 months, with a median of 23.775 months. However, these are just assumptions and do not reflect current quotes, burn rates, or management forecasts. The test does not include liabilities, taxes, fees, existing cash, milestones, or changes in trial costs. The conclusion is that the data cannot validate the precise runway or loss limit, and actual cash and trial budget are needed. The main constraint remains a positive payoff, with a quarter Kelly of 0. The sources of the data are https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=IPHA&timeframe=1Day&feed=sip&adjustment=all and https://www.sec.gov/Archives/edgar/data/1598599/000162828026057935/exhibit993.htm.

A news scan found the headline 'IPHA affordable whole shares fail liquidity and trend gates'. This refers to a stock called IPHA. On September 9, the adjusted close price was 1.95. The 20-day simple moving average, which is a way to smooth out price changes, was 2.186, and the 50-day simple moving average was 1.960094. The return over 20 sessions was -9.30233%, and the average daily range, or ADR, which is a measure of price volatility, was 20.10406. The simple average true range, or ATR, which is another measure of volatility, was 14.105614. The daily turnover volume times the volume-weighted average price, or VWAP, was 48,082.05, and the 20-day median was 56,610.23. The old median was 46,881.90, which uses the close price times the volume. There are two possible entry points, one at 1.84594 and one at 2.10609, but these are just examples, not actual orders. The fund has 49.14, which allows for the purchase of 25 shares before fees, but this does not mean permission to buy has been given. Historically, the stock has had a negative cost and a holdout since 1997, with all 18 historical median volumes being less than 1 million. There is no executable bid or ask, and no order book has been measured. As a result, there is no approved size and no invented live stop or target. Just because the stock is affordable does not mean it has an edge, or an advantage. The daily liquidity proxy, which is a measure of how easily the stock can be bought or sold, does not include European ordinary share volume and does not prove that 49 USD is unfillable. The Euronext exchange may be more liquid, but the venue and foreign exchange, or FX, have not been validated and cannot transfer American Depositary Share, or ADS, returns automatically. One argument against this is that new partner funding could improve the tape, or the record of trading activity, but this would require a price and liquidity, as well as an independent payoff, rather than just a lower threshold. The data can be found at https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=IPHA&timeframe=1Day&feed=sip&adjustment=all.

A study of IPHA events found no positive edge. The analysis used a frozen six-event holdout from 1997, which had a mean of -1.61159% and a 95% empirical bootstrap interval of -6.34633% to 3.30274%. The study used 50,000 samples and a NumPy seed of 2026091004. However, the small number of same-issuer observations and reused market periods limited the independence of the data, and no population FDA hazard or post-Sobi probability could be inferred. The study also compared time-only net returns with identical SPY windows, finding a mean excess of -4.10849 percentage points, a correlation of 0.401166, and an OLS beta of 1.621565 with an intercept of -5.07762% per window. The study noted that the six observations were descriptive, not a stable factor model, and no selection or refit followed these coefficients. Additionally, the study found that the issuance of new ordinary shares, totaling 17,647,059, resulted in an 18.75666% increase in share count, and existing ownership fell by 15.79420% after a total of 111,731,269 shares. The issuance costs were EUR 2.4 million, with a gross of EUR 30 million and a net of EUR 27.6 million, representing an 8% cost. The study concluded that rates and totals are different concepts. The Live Catalyst ledger showed three losses and two operator-censored exits, with no observed mean winner, resulting in a quarter Kelly clip of 0 under the tested payoff and an undefined value for the new funding regime. The study emphasized that strong countercase financing changes the distribution and requires independent observations, rather than treating narrative as measured edge. The sources used in the study included data from https://runway.adityaperswal.workers.dev and https://www.sec.gov, as well as the runway query trades fund catalyst.

A trading strategy test was run on the IPHA stock using a momentum strategy, which means it looks for stocks that are moving up or down quickly. The test used 20 days of past data to make decisions, and it was run over 1800 days. The test stopped trading when losses reached 5% and took profits when gains reached 7.5%. The test used 1157 pieces of data from the IEX exchange and made 110 trades. The result was a return of -75.247754%, which means the strategy lost money. The biggest loss was 75.762795%, and 25.454545% of trades were winners. On average, each trade lost 1.150144%. If the stock had just been bought and held, it would have lost 65.694683%. This result is the same as a previous test in 1941, and it does not show any new or independent advantage. The test did not include all costs and did not set aside separate data to validate the results, which is a limitation. The test also did not check if trades could be executed at the desired price within 15 minutes. This test is only a diagnostic tool, and a separate study that includes costs and uses a different time period also failed. Running the test again did not change the result. The data used for the test can be found at https://runway.adityaperswal.workers.dev/data/stock-bars?feed=iex&timeframe=1Day.

A news scan found the headline about IPHA's preregistered financial calendar T5/T1 failing a train and chronological holdout. The premises of this note involve 18 advance calendar reports from 2022 to May 2026, with 12 reports from 2022 to 2025 used for training and 6 reports from 2025 to 2026 used for holdout, with no events selected based on return. The sources of this information are five issuer annual calendar observations from 1995 to 1999, all of which were made before the CET open and did not include any AGM or future events. The strategy used was to buy on the 5th US prior open and sell on the last prior close, or use a 1 ADR 20 stop and 1.5 ADR 20 target, with a prior 20 only and gap open precedence, and stop first in intraday ambiguity, which is a trading term that means stopping a trade at the first sign of ambiguity during the day. The vectorbt, a backtesting library, was used for long only cash, reinvesting non-overlapping trades, with fees of 10 basis points per side and slippage of 25 basis points for the base case and 50 basis points for the stress case. All 72 event outcomes were reconciled using a cash formula, and 8 portfolio totals were calculated, with an initial default short bug caught and corrected before recording. The results showed a base barrier train of -29.0994% and a drawdown of 30.3031%, and a holdout of -10.4636% and a drawdown of 12.1874%, with a p-value of 33.3333%, a win rate of 7.67464%, and a loss rate of 6.25470%, and a mean return of -1.61159%, with a bootstrap confidence interval of [-6.34633, 3.30274]%. The stress holdout was -13.1098%, and the time only base was -15.1724% and the stress was -17.6795%. All 8 split/mode/cost cells were negative, and the raw quarter Kelly was 0. The conclusion was to reject and not retune. The limitations of this study include only one issuer, a small sample size of N6, calendar revision and early pipeline archive incompleteness, and 20-day dollar volatility all less than 1 million, and not being a Sobi-financing-conditioned cohort. The synthetic open/close mark DD does not capture all intraday DD, and daily touch fills and fractional abstract capital with no plus 1 R partial not venue execution were not considered. The fees and slippage assumptions were also unknown, and actual quotes were not available. A counterexample of a changed funding regime could alter the future payoff, and this needs an independent cohort, and is not an invalidation of the negative observed test. The data can be found at https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=IPHA,SPY&timeframe=1Day&feed=sip&adjustment=all, and the inputs and results can be found in the code /tmp/codex-run-EyESFK/ipha_test.py. There is no order.

The company's financing situation has been corrected to show a conditional runway through Q1 2028, not a cash receipt or fully funded Phase 3. This is based on three premises: first, the August 14 offering exhibit projects a runway through Q1 2028 using equity plus a $75m payment from Sobi; second, the August 19 filing confirms that equity was completed on August 18, with a net of EUR 27.6m expected, and that the priority is ADC development, not just lacutamab; and third, the Sobi/Innate joint agreement on August 10 gives commercial rights on potential accelerated approval and an option to assume full development after positive Phase 3. The latest financial assets as of March 31 are EUR 25.4m, including EUR 4.9m short-term and EUR 10.4m non-current, with a cash residual of EUR 10.1m. The conclusion is to replace the baseline of an imminent unfunded company with a materially improved conditional runway, but not to assert completion of funding or actual receipt of $75m. The soundness of this conclusion is based on official issuers, but they are incentivized and joint copies are not independent. The validity of the runway forecast cannot logically imply fully funded randomized completion. A counterargument is that future milestones and royalties could finance completion, making the future funding gap unknown rather than certain. The next report on September 17 must reconcile closing, subsequent events, cash definition, burn, and trial commitments. There is no approval probability or stock target from the funding headline.

The fund started with $49.14 in cash and $850.99 in equity, and no holdings. The goal is to make repeatable gains before events happen, while keeping costs low, which is called an independent edge. The fund looked at 13,160 non-test securities, which are investments that are not being tested, and excluded 543 special format securities. It queried 6,956 securities and got 6,577 price bars, which are pieces of price data, back, but excluded 184 stale ones, leaving 6,393 fresh ones. The fund also looked at 2,520 prices between $1 and $49.14. It preserved 6,577 rounded data points, but did not have complete data on US common stocks, over-the-counter stocks, or calendars. The fund rejected some top price leaders, including SUNE, because its 2027 and 2028 earnings are not dated, and YMATF, because it is not on a calendar. It also rejected FTFT, because its latest 8K split is not a future date, and IRD, because its data was already released on September 9. The fund noted that ODD's earnings were on September 9, and PHGE's raw split was 945%, which becomes 4.516% after adjustment. The fund checked some primary URLs, including 19174, 19176, 19358, 19671, and 19744-46. The fund tested a new earnings per share model on September 15, which rejected AMC with a -6.551% result, and N6 with a +3.823% mean result. The fund confirmed IPHA's report on September 17, and updated its Sobi 75m conditional cash and 27.6m EUR raise, which improved its fundamentals, but failed a dollar volume screen on September 9. The fund checked overseas quotes, including UKBTRW on September 16, and NXT and KGF, which are existing watches. The fund also checked crypto pairs, but found no qualified earnings or FDA edge. In conclusion, the fund did not make any orders or proposals, and did not fabricate any stops. The fund's validity is limited by possible missed opportunities, and its soundness is limited by survivorship bias, missing calendar and identifier data, and 15-minute execution. The fund's new breadth changed its watchlist, but not its risk allocation. The fund capped its discovery at 12 minutes, with gaps, and reserved its finish, but did not spend it on an exhaustive market claim. The fund's sources include the Nasdaq trader website, the Barratt Redrow website, and the Ethereum Magicians website.

A news scan found the headline about a signed partnership between Innate Pharma and Sobi, which changes the financing context for Innate Pharma. This partnership, announced on August 10, promises $75 million upon closing, up to $40 million in the near term, and $465 million in further milestones and options, with tiered double-digit royalties. The closing conditions include antitrust clearance. Innate Pharma will conduct the TELLOMAK 3 trial, and Sobi will get global commercial rights upon potential accelerated approval. On August 18, Innate Pharma raised 27.6 million euros in equity, which is distinct from the conditional payment of $75 million and the 25.4 million euros in financial assets from March. This partnership provides a better funding framework than in May, but the current cash, receipt, burn, and retained value are still unknown. The total headline value of $580 million is not cash today, and no probability or sum has been invented. The partnership could support a stock run-up, but the executable price edge and liquidity still fail, with a trading volume of $46.9 thousand on September 9 and a 20-day median of $56.9 thousand. As a result, Sobi will absorb the commercial role, Innate Pharma can gear trial spending to committed funding if the deal closes, and retained royalty economics will depend on success and terms rather than full product revenue. The sources for this information are the press releases from Sobi and Innate Pharma, as well as a conference source from the SEC website, which confirms a clinical update on September 14 at 16:30 EDT, but does not promise new clinical data.

The automated trading fund manager has identified three-step cash and ownership chains from the wider catalyst screen. The first step is the EPM conditional chain, which involves mineral sellers exchanging future cash for partly new equity, with 16m funded. The second step is that projected asset cash of 3.9m must clear corporate and financing costs and dividends. The third step is that existing holders benefit only if per-share cash improves faster than dilution. However, if there are lower prices or operator completion delays, it can reduce coverage and force capital allocation changes. For IPHA, on August 27, 6m expected net funds are for IPH4502 development, and program prioritization and runway improvement are expected, but new ordinary shares will dilute existing holdings. The future partnership and clinical value capture depend on trial data, not the financing headline. If there is a faster burn or failed trials, it can consume the added runway. For GSK, the completed NUVLA acquisition transfers assets, and the September 18 decision affects launch economics inside GSK. The parent stock response is diluted by the broader franchise, with no NUVLA standalone run-up. For SUNE, the announced plant capacity requires funding and construction, and execution through late 2027 or 2028 determines usable output. Cash returns depend on paid cell orders and margins, not the September 9 price velocity. These are inferences, with no probabilities assigned. The beneficiaries are asset sellers and placement agents who receive cash now, while stockholders bear commodity, trial, and build risk. A counterargument is that operating execution could surpass assumptions, and it is necessary to measure actual cash and costed stock edge. The sources of this information are from the news releases and filings of Evolution Petroleum, GSK, and other companies.

A news scan found the headline 'Positive selected-holdout bootstrap is not permission to risk capital'. This refers to a type of statistical test. A test called Premise1 found that a costed 6 event holdout from 1928 has a positive point estimate, but the training data was negative and the mean confidence interval crosses zero. Another test, Premise2, used a NumPy seed of 2026091003 to resample 6 stress returns independently 50,000 times, with 10 events, an initial value of 49.14, and a raw holdout quarter Kelly of 0.063805896 per event. The mean was 49.352116, with percentiles 05/50/95 of 48.845875/49.352178/49.856086, and a loss of 24.838%. No simulated paths reached 398.15, which is 349.01 more than the initial value, but this is not a 22-day forecast or proof that it is impossible. This is because the test did not model event frequency, unseen tails, dependence, costs, and regimes. The conclusion is that the actual approved allocation is 0. The validity of this test is that optimistic resampling does not fix negative training or uncertainty, and soundness is only conditional on the empirical sample. A counter case with an independent prospective history may increase confidence, but the current holdout should not be retuned. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=EPM&feed=sip&adjustment=all, which includes actual issuer dates of 19625.

A diagnostic test for the momentum trading strategy on the stocks EPM and IPHA failed before considering costs. The test used a command line interface, or CLI, with the following settings: node /app/agent/dist/backtest.js --symbols EPM,IPHA --strategy momentum --lookback 20 --days 1800 --stop-pct 5 --target-pct 7.5. This test, called Premise1, used default adjustments from IEX and did not account for fees or slippage, which refers to the difference between expected and actual trade prices. The test analyzed 1157 bars of data and made 110 trades. The results showed a gross return of -75.2478%, a drawdown of 75.7628%, a win rate of 25.4545%, and an average return of -1.1501%. The conclusion was that the momentum diagnostic failed, and it did not make an independent claim about the strategy's performance outside of the test period, known as out-of-sample, or OOS. It also did not use the results to determine the size of trades. A separate test, called 1928, will use a different method, including costs and a frozen training period from 2024 and a holdout period from 2025-26, to validate the trading strategy. This test will also examine the performance of a counter case with a pre-event rule. The data for the test comes from https://runway.adityaperswal.workers.dev/data/stock-bars?feed=iex&timeframe=1Day, which is a source of stock bar data.

A diagnostic test was run using the command line interface, which executed the command node /app/agent/dist/backtest.js with the following parameters: symbols EPM and IPHA, strategy momentum, lookback 20, days 1800, stop percentage 5, and target percentage 7.5. The test used two premises, with the first premise using the IEX default adjustment and no explicit fee or slippage, resulting in 1236 bars and 109 trades. The second premise had a gross return of -51.8445%, a drawdown of 67.3506%, a win rate of 32.1101%, and an average return of -0.5521%. The diagnostic test was rejected because it did not validate the catalyst trade independently and did not make any out-of-sample claims, and it was not used for sizing. A separate test, 1928, uses SIP and vectorbt, and includes costs and a frozen train and holdout period from 2024 to 2025-26. This test may produce different results, which will be tested separately. The data source for this test is https://runway.adityaperswal.workers.dev/data/stock-bars?feed=iex&timeframe=1Day, which is a stock bars data feed from IEX with a 1-day timeframe.

A news scan found the headline about Evolution Petroleum's earnings. The automated trading fund manager made some decisions about buying and selling the company's stock, which is traded as EPM. The manager looked at the stock's performance before and after the company announced its earnings on the actual issuer date, which was 19625. The manager decided to buy the stock at the opening price three days before the announcement and sell it at the closing price one day before the announcement, with a preferred stop at 1 prior to 20 ADR and a target at 1.5 ADR. The manager used data from 2024 for training and from May 2026 for testing, with an adjusted SIP. The manager also considered fees of 5 basis points per side and a slip of 10 basis points for the base case and 25 basis points for the stress case. The manager used a daily high and low stop, and a gap stop at the minimum of the open and stop prices, with a conservative target. The manager used a system called Vectorbt to reproduce the costed ledger, with two fill observations per event. The manager found that the preferred training return was -5.422920% for the base case and -6.551066% for the stress case. The holdout return was +5.708773% for the base case and +3.823032% for the stress case, with the stress case winning 4 out of 6 times, with an average win of 2.643210% and an average loss of 3.262591%. The manager also found that the mean return was 0.674609%, with a 95% confidence interval of [-1.778946, 3.065121]%. The manager found that the event-close drawdown was 3.668236%, and the Vectorbt sampled drawdown was 3.956487%. The manager concluded that the strategy should be rejected for live trading, with a raw holdout quarter Kelly of 0.063806, because it failed the training, uncertainty, and execution tests. The manager noted that a strong counterargument is that the royalty mix may have changed, which could make the 2024 data stale, and that prospective proof is needed, not retrospective deletion. The manager verified the dates retrospectively and found that the advance announcement, early news, and dividend execution were complete, but that there was a gap in the audit. The manager used data from https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=EPM&feed=sip&adjustment=all&timeframe=1Day and https://ir.evolutionpetroleum.com/news-events/news-releases, and found a future announcement scheduled for September 15 AM at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-schedules-fiscal-q4-and-full-year-2026.

A study on commodity exposure and its effect on earnings found no evidence that being affordable or exposed to certain market factors creates an edge in predicting earnings. The study used a statistical method called ordinary least squares, or OLS, to analyze the daily adjusted returns of 252 matched days. The results showed an alpha of -0.243994% per day and a beta of 0.045827 for the SPY, which is a measure of volatility, and a beta of 1.011687 for the XLE, which is an energy sector index. Another set of results showed an alpha of -0.003762% and a beta of 1.634852 for the SPY and 0.171132 for the XLE. These results are descriptive and do not claim to predict any future events or significance. The study also analyzed the two-day returns of 6,393 securities from September 8 to 9 and found a median return of -0.88665%. The study concluded that merely being affordable or exposed to certain market factors does not create an edge in predicting earnings. The study suggests that company-specific news can overwhelm sector trends and that a costed event sample is needed to independently verify the results. The data for this study came from a source at https://runway.adityaperswal.workers.dev/data/stock-bars and a query of trades from a fund called catalyst.

A news scan found the headline about EPM and IPHA trends. EPM completed its SIP on September 9 with a price of 3.69. The Simple Moving Average, or SMA, over 20 days was 3.6365 and over 50 days was 3.6822. The Relative Strength Index, or RSI, over 14 days was 51.84, and the return over 20 sessions was -2.122%. These indicators do not clearly show which direction the price will move. The Average Daily Range, or ADR, over 20 days was 0.11124, which is 3.0146% of the price. This means that a price move of 0.11124 to 0.16686 could happen, but it is not a prediction or a guaranteed outcome. For IPHA, the price on September 9 was 1.95, which is below the SMA of 2.186. The RSI was 43.626, and the return over 20 sessions was -9.3023%. The median dollar volume was 56,938, and on September 9 it was 46,882, which is below the required liquidity floor. Overnight stops can be checked every 15 minutes and can have gaps in the price. Neither using a daily bar proxy nor a whole-share lot can guarantee that the risk will be limited to 1%. In conclusion, EPM is being watched and IPHA's liquidity is being rejected, so the target will not be widened to make up for the lack of profit. However, if there is a high-volume release, it could change the execution for IPHA, but it would require a fresh spread and depth, and a new independent edge. The data comes from https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=EPM,IPHA&timeframe=1Day&feed=sip&adjustment=all and the EPM date from https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-schedules-fiscal-q4-and-full-year-2026.

A news scan found the report that two companies, Premise1 and Premise2, also known as EPM, and IPHA, have new earnings information. EPM's operating cash flow, which is the cash a company generates from its operations, for the third quarter, which ended on March 31, was $3.5 million, and after subtracting $1.6 million in capital expenditures, which are expenses to maintain or improve assets, the company had $1.9 million, which was not enough to cover the $4.3 million in dividends, resulting in a 44.19% coverage and a $2.4 million deficit before acquisitions. On August 20, EPM acquired a company for $16 million, which is expected to generate $3.9 million in cash over the next twelve months, but this estimate excludes general and administrative expenses, which are the costs of running a company, and assumes certain oil and gas prices and development costs. On August 19, EPM offered 3.7 million shares at $3.25, which added $12.025 million to the company's gross assets. The asset acquisition was effective on August 1, which is after the June 30 report period, so the financials released on September 15 cannot include its full subsequent cash benefit. IPHA had $25.4 million in cash on March 25, which includes $10.4 million in non-current financial assets, which are assets that are not expected to be converted into cash within a year. On August 18, IPHA closed a financing deal that added $27.6 million in expected net cash, but this is not current cash, so the total cash is $25.4 million plus $27.6 million. No new American Depositary Shares, which are shares of a foreign company that are traded on a US exchange, were issued, and new ordinary shares are barred from being deposited into an American Depositary Share, so it cannot be assumed that the shares are fungible, which means they can be easily exchanged for other shares. In conclusion, both companies have credible and dated reporting events, but there is no independently validated price edge, which is an advantage in pricing, or precise current enterprise value to free cash flow valuation, which is a measure of a company's value. A strong counter-case is that EPM's restored production and royalty mix could improve per-share cash, and IPHA's financing removes near-term constraints, and clinical data could help. What would move the prior assessment is if EPM's free cash flow covers its dividend without new funding and has a positive costed regime history, and if IPHA has a post-raise balance, a full pipeline, and an actual event history. The sources of this information are the companies' websites and the Securities and Exchange Commission website. The validity of this information is that financial constraints do not prove negative price returns, but only support withholding an uncalibrated trade. The soundness of this information is that the issuer's forward estimates are not independent verification.

The fund started with $49.14 in cash and $850.99 in equity, and had zero holdings or pending trades verified as of 18633. The goal is to achieve repeatable gains before events, with a binding constraint of having a positive executable edge. Three premises were considered: 1804 failed costed samples with zero Kelly criterion, 1803 new KFY recast and recovered AVO feed did not establish a price edge, and 1805 date certainty does not bound binary gaps. A Kelly criterion is a measure of risk and return. Therefore, no proposals or exit adjustments were made. The validity of the decision follows the mandate, but the soundness is limited due to a small sample size, incomplete news and valuation coverage, and sparse execution history. A strong counterargument is that holding cash misses opportunities, but no calibrated probability of win or loss was supplied. No new test is warranted for the unchanged rejected rule, and CLI 1688 and costed vectorbt 1158/1677 remain frozen. Monitor 153 was resolved, and reviews were armed for AVO on October 8, with 137/22 and five jobs retained. The source URLs are in 1803-07/18628-33, and no orders were placed. The journal phase took 00:02:51, within the 31-minute plan and 45-minute hard limit. No separate book was justified.